An experimental drug that Genentech Inc. and parent company Roche had hoped would clear away clumps of proteins in the brains of Alzheimer's Disease patients failed two late-stage clinical trials.
Gantenerumab, Genentech's monoclonal antibody, had failed a previous Phase III study with Genentech drug-discovery partner MorphoSys. The trials focused on people with mild cognitive impairment due to Alzheimer's and with mild Alzheimer's dementia.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Most Admired CEOs: John Sensiba of Sensiba San Filippo LLP - San Francisco Business TimesSensiba San Filippo LLP Managing Partner John Sensiba talks growth and becoming a B Corp: 'We went from 190 people at the beginning of the pandemic in our firm to over 350 people today.'
続きを読む »
San Francisco's newest condo developments reap diverging fortunes - San Francisco Business TimesWhile some towers are at or near capacity, other developments, especially South of Market, have multiple units unsold. Vancancy tax will help. Lmao.
続きを読む »
State regulations move to change solar power pay structure - San Francisco Business TimesThe California Public Utilities Commission has just thrown a curveball at the solar industry.
続きを読む »
Most Admired CEOs: Robert Sanchez of Casa Sanchez Foods - San Francisco Business TimesThe third generation leader of one of the Bay Area's most prominent family businesses dishes on the secrets of lasting success. It's great to hear a positive story about a product I've enjoyed for years.
続きを読む »
Most Admired CEOs: Jacqueline Garcel of Latino Community Foundation - San Francisco Business TimesJacqueline Martinez Garcel was born in Washington Heights in Manhattan, but her family moved back to the Dominican Republic when she was young. Her identity was sealed.
続きを読む »